Engflag

Primidona

Quick links to important sections

Primidona

Primidona_FR

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Primidona

What is Primidona? Defining the Anticonvulsant Entity

Property Description
Active Ingredient Primidone (INN)
Form Oral tablets, Oral suspension
Pharmacological Class Anticonvulsant, Barbiturate Derivative
Common Use Control of abnormal neuronal activity (e.g., seizures, tremor)
Origin Synthetic Compound

What Type of Medicine is Primidona (Primidone)?

Primidona refers to the active ingredient Primidone, a synthetic compound classified as an Anticonvulsant or Antiepileptic Drug (AED), and designated as prescription-only (Rx Only status in the U.S.). The most widely recognized brand name is Mysoline, though generic versions of the tablet are readily available from multiple global manufacturers, differentiating its commercial availability from its chemical identity. The drug is supplied as a single-ingredient product for oral administration, typically available as tablets or an oral suspension.

Understanding the Origin and Unique Chemical Nature

Primidone is chemically defined as a barbiturate derivative, which distinguishes it from many contemporary anticonvulsants. Its unique functionality stems from its status as a prodrug. This conversion process generates two primary active metabolites—phenobarbital and phenylethylmalonamide—both of which contribute to the drug's therapeutic profile, providing a sustained, multi-faceted action on the central nervous system (CNS).

Primary General Purpose and Therapeutic Classification

The general purpose of this Anticonvulsant class is to suppress the abnormal, rapid, and synchronized firing of neurons, thereby stabilizing the underlying cause of sudden neurological events. Primidone is clinically recognized for its efficacy in managing conditions characterized by neuronal overactivity, achieving electrical balance by enhancing the inhibitory effects of the Gamma-aminobutyric acid neurotransmitter. A common use scenario is its application as a first-line therapy for patients managing chronic essential tremor. This stabilizing function makes it a valuable tool for controlling the involuntary muscle contractions and excessive signaling found in conditions like epilepsy and tremor.

Regulatory References

  1. NIH DailyMed Entry for Primidone

What side effects are possible with Primidona?

Possible Side Effects and Safety Information

The safety profile of Primidone, a barbiturate derivative, is defined by classifications and warnings documented in official regulatory sources. The adverse reactions are officially grouped by the frequency of occurrence and the physiological systems affected.

Frequency and Systemic Classification

Side effects are most frequently observed early in the course of treatment. Ataxia (unsteady gait) and Vertigo are noted as the most frequent initial effects, which typically diminish or disappear with continued therapy. Other common reactions documented in official labeling include Drowsiness (somnolence) and Nystagmus (involuntary eye movement). Reactions affecting the Gastrointestinal System (Nausea, Vomiting) and Skin and Subcutaneous Tissue (skin rash) are also reported.

Serious Adverse Reactions and Safety Constraints

Official prescribing information highlights rare but clinically significant adverse reactions. Primidone carries the class-wide warning for all Antiepileptic Drugs (AEDs) concerning the increased risk of Suicidal Thoughts or Behavior, which may be observed throughout the treatment period. Rare reports of severe, life-threatening skin conditions, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have also been documented. Additionally, rare Blood Dyscrasias (e.g., Agranulocytosis, Aplastic Anemia) are noted.

Primidone is formally contraindicated in patients with a known hypersensitivity to the medicine or its primary metabolite, Phenobarbital, and in individuals with a history of Porphyria. Furthermore, regulatory notes advise that abrupt discontinuation carries the risk of precipitating seizures or status epilepticus.

Population-Specific Safety Notes

The label specifies safety considerations for certain groups. For pregnant patients, the drug is associated with potential fetal harm and risk of neonatal hemorrhage. Older adults may require lower doses to prevent oversedation, and there is a documented potential for paradoxical excitement in both older adults and children.

Overdose and Emergency Response

Primidona overdose manifestations are primarily classified by regulatory authorities as severe depressant effects on the Central Nervous System (CNS). Documented signs include a progressive spectrum of symptoms such as confusion, drowsiness, stupor, and the potential for coma. Neurological clinical manifestations like ataxia (unsteadiness), nystagmus (uncontrolled eye movements), and diplopia (double vision) are also officially noted in prescribing information.

In severe overexposure scenarios, documented life-threatening outcomes involve the respiratory system and cardiovascular system. These include respiratory depression and hypotension (low blood pressure), alongside potential complications such as renal failure.

Regulatory labeling provides explicit guidance on emergency response: individuals must seek immediate medical attention and call emergency services or a Poison Control center if an overdose is suspected or if more than the normal prescribed dose is taken. This mandatory action is required due to the severity of the possible complications. Management, as described in official prescribing information, consists solely of symptomatic and supportive treatment, as regulatory documents state that no specific antidote is known. This supportive care focuses on managing the life-threatening manifestations and ensuring the removal of unabsorbed drug.

Therapeutic Uses of Primidona

What Primidona treats: Main Uses and Benefits

Primidona is commonly used to address conditions involving symptoms of increased neurological or muscular activity. The medication is relevant for easing symptoms across two main therapeutic domains: epilepsy and seizure disorders and the management of Essential Tremor (ET).

It is applied in clinical settings that involve recurrent or episodic manifestations. For seizure disorders, the medication provides supportive relief that helps in managing seizure control. For Essential Tremor, it is commonly used to help with the involuntary shaking of the hands or limbs that may become disruptive during voluntary actions, such as generalized tonic-clonic and partial (focal) seizures.

The use of Primidona is relevant for managing symptoms that interfere with daily comfort and is generally applied when supportive symptom management is appropriate. The medication generally contributes to improved comfort during periods when symptoms are more noticeable and may assist with supporting functional stability, contributing to easing the overall symptom load. It is also applied as an adjunctive therapy in cases of difficult-to-manage, refractory symptoms.

Quick Fact: Symptom Management Contexts
Primidona may assist with supporting functional stability, contributing to easing the overall symptom load of kinetic tremor and convulsive seizures.

Regulatory References

  1. StatPearls – Primidone (NCBI Bookshelf)

Eligibility and Restrictions for Use

The eligibility for Primidona use is strictly defined by government regulatory documents, outlining populations that are permitted, restricted, or absolutely prohibited from using the medicine.

Contraindicated Populations

Use is contraindicated in patients with a history of porphyria or those with known hypersensitivity to Primidona, its metabolite phenobarbital, or any barbituric acid derivatives [1.1, 2.3]. Some regulatory labels also cite severe respiratory depression and sleep apnea as contraindications [1.3, 3.1].

Age and Organ Function Restrictions

Population Group Regulatory Status
Adults Established for use [1.1].
Children under 8 years Use requires caution [2.1]. Safety in this age group is not established by some authorities [3.1].
Geriatric Patients Use requires caution; lower doses are required to preclude oversedation [1.5, 3.1].
Renal/Hepatic Impairment Use requires caution; dosage must be adjusted [2.1, 3.5].

Pregnancy and Lactation

Primidona is classified with a risk to the fetus (e.g., FDA Pregnancy Category D). It is associated with an elevated incidence of birth defects and neonatal hemorrhage [1.1, 1.6]. It appears in substantial quantities in breast milk; regulatory documents suggest discontinuing nursing if the infant exhibits undue somnolence [1.1]. Women of childbearing potential should be advised to use alternative highly effective contraception [2.3].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Primidona is strictly contraindicated in patients with porphyria and those hypersensitive to the drug or its active metabolite, phenobarbital. Co-administration is also prohibited with numerous therapeutic agents, including certain antivirals (e.g., Atazanavir) and antimalarials, because Primidona significantly decreases their plasma concentrations, resulting in a loss of efficacy.

The core of the interaction profile is defined by Primidona and phenobarbital, which are potent inducers of liver enzymes, primarily the CYP450 3A4 system. This induction accelerates the metabolism of many co-administered medicines, including oral contraceptives and Warfarin, leading to their reduced exposure or reduced effectiveness. Conversely, inhibitors like Valproic Acid may increase plasma levels of Primidona and phenobarbital.

Official labeling notes an additive CNS depressant effect when co-administered with alcohol or other CNS depressants. Use with St. John's Wort is not recommended due to its own enzyme induction properties. The drug is also officially associated with reduced serum levels of essential nutrients, specifically Folic Acid and Vitamin D. Furthermore, a restriction states that certain hormonal contraceptives must not be used for at least 28 days after discontinuation of Primidona. Use during pregnancy is formally noted for the risk of coagulation defects in newborns.

Mechanism of Action

Primidone's Dual Mechanism: Direct Action and Active Metabolites

Primidone engages mechanisms that regulate overactive or dysregulated processes in the central nervous system through two primary modes. The compound is active itself but also undergoes significant hepatic metabolism, leading to the formation of two pharmacologically active metabolites: phenobarbital and phenylethylmalonamide (PEMA). This dual activity contributes to influencing the frequency and amplitude of neuronal firing within the CNS.

GABA A Receptor Positive Modulation

A key mechanistic domain involves the modulation of systems where specific inhibitory transmitters dominate, namely GABA (gamma-aminobutyric acid). Primidone's primary active metabolite, phenobarbital, initiates or suppresses signaling sequences by acting as a positive allosteric modulator at the GABA A receptor

. This action potentiates GABA's natural inhibitory effect, increasing the duration of chloride channel opening and leading to neuronal hyperpolarization. This results in reduced postsynaptic excitability within targeted pathways, modulating the influence of excitatory mediator activity.

Modulation of Voltage-Gated Channels

Primidone and its metabolites also engage mechanisms that influence feedback regulation within pathways associated with heightened physiological responses. This involves an additional, complex mechanism that contributes to inhibition of neuronal hyperexcitability. The drug and its metabolites are relevant in cascades where multiple layers of pathway activation occur, resulting in suppression of rapid, repetitive firing of neurons by altering early molecular steps, such as modulating voltage-gated sodium or calcium currents. This action affects systems where specific transmitters or mediators dominate, leading to measurable changes in neuronal electrophysiology that decrease the frequency of neuronal action potentials.

Dosage and Administration Information

Official Instructions for Primidona Use

Primidona is an oral medication that must be used strictly according to a gradual, regulated schedule as established in standardized clinical protocols.

Administration Scope

Element Official Guideline
Route of Administration Oral administration only.
Standard Initial Dose (Adults) Starts with 100 mg to 125 mg once daily at bedtime for the first three days.
Maintenance Dose Range Typically 750 mg to 1500 mg daily, administered in divided doses. Maximum daily dose is 2000 mg for seizures.
Essential Tremor Limit Maximum daily dose for this use should generally not exceed 750 mg.
Timing with Meals The medicine may be taken with or without food.

Procedural and Populational Rules

The total daily dose is usually administered in divided doses across the day, though the dose can be adjusted to allow the majority to be taken in the evening if required.

Age-Group Administration: A lower starting dose of 50 mg at bedtime is specified for children under 8 years of age. Older adults should also initiate treatment at lower doses.

Discontinuation: The medicine must never be stopped abruptly. Standard clinical protocols require that the dose be gradually decreased over a period of not less than two weeks when ceasing treatment or transitioning to monotherapy.

Missed Dose: If a dose is missed and it is nearly time for the next scheduled dose, the missed dose must be skipped to avoid a double dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Primidona

Evidence for Use in Essential Tremor

Research on Primidona for Essential Tremor was evaluated and includes Randomized Controlled Trials (RCTs). These studies typically enrolled populations of adults managing Essential Tremor, a condition marked by functional limitations due to involuntary shaking. The research focused on measuring changes in tremor amplitude and scores on standardized functional scales (e.g., TETRAS) over defined time intervals. Findings from these trials describe patterns observed in the measured tremor severity scores and objective tremor amplitude metrics following short- to intermediate-term administration. However, research exploring short-term symptom changes also reported that patients in some studies had high rates of discontinuation, largely due to participants experiencing acute central nervous system-related events.

Evidence for Use in Epilepsy and Seizure Disorders

Primidona was studied for use in people managing conditions characterized by fluctuating or episodic manifestations, specifically Focal (Partial) Seizures and Generalized Tonic-Clonic Seizures. The evidence was derived from Controlled Clinical Trials and Comparative Effectiveness Studies against other anti-epileptic drugs. These studies monitored outcomes related to the frequency of seizure occurrence and the proportion of patients achieving periods of seizure freedom. Findings describe patterns observed in the studies regarding seizure frequency following its use in patients with partial and generalized seizures. Studies reported differences in the tolerability profiles, with some comparative trials describing differences in the incidence of sedative or cognitive changes. Given the age of some core trials, the evidence quality varies across studies, and many of the older studies do not include modern quality-of-life outcomes.

Limitations, Evidence Gaps, and Areas for Future Research

Regulatory and peer-reviewed scientific literature highlights several areas where the evidence is limited or research is still needed. For Essential Tremor, research is lacking regarding its application to non-limb tremors, such as head or voice tremor. The follow-up durations for many key outcome studies were limited, meaning there is limited information for long-term outcomes over many years of continuous use. Furthermore, comparative evidence against the newest anti-epileptic drugs is lacking in certain areas, particularly when assessing long-term quality-of-life or cognitive outcomes. These research limitations mean that findings describe group patterns and reflect the specific conditions under which the studies were conducted, but they do not determine whether an individual will respond similarly. This evidence highlights what is known—and what is still uncertain.

Key Studies & References

  1. Primidone Tablets, USP Official Prescribing Information (Indications, Dosage, Adverse Reactions)
  2. Primidone - LiverTox (NIH resource discussing liver safety and long-term adverse effects)

Frequently Asked Questions (FAQ)

Common questions about Primidona (FAQ)

Q: Does Primidona require therapeutic drug monitoring (TDM)?

According to official product information, Primidona may require Therapeutic Drug Monitoring (TDM). TDM involves testing to measure the amount of the drug in your blood. Monitoring may be recommended because the drug's effectiveness and potential for side effects are closely related to its concentration in the bloodstream.

Q: Can Primidona treatment be stopped abruptly?

Regulatory documents advise that Primidona treatment should not be stopped abruptly. Suddenly stopping this medication can lead to serious consequences, including the possibility of increased seizure activity (status epilepticus). Changes to or discontinuation of therapy should follow a gradual schedule as determined by a healthcare provider.

Q: Is Primidona known to cause any dependency?

Official product information notes that Primidona has the potential for causing dependence and abuse. This means there is a risk of developing a physical or psychological need for the drug. Due to this potential for dependence and abuse, Primidona is classified as a controlled medication.

Q: Does Primidona affect the liver or kidneys?

Studies and official information indicate that Primidona should be used with caution in patients with impaired hepatic (liver) or renal (kidney) function. Dosage adjustments may be considered for people with these conditions. Monitoring of liver and kidney function may be advisable during treatment for individuals with pre-existing conditions.

How should Primidona be stored and disposed of?

How to Store and Dispose of Primidona?

The storage and disposal of Primidona must adhere strictly to the conditions mandated in official regulatory labeling to ensure product stability and safety.

Official Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, generally 20 C to 25 C (68 F to 77 F). Avoid storing the medicine where it can freeze or be exposed to excess heat.
Container Keep the tablets or suspension in the original container, ensuring it is tightly closed and protected from light and moisture.
Safety It is mandatory to keep the medicine out of the sight and reach of children.

Disposal Instructions

To discard unused or expired Primidona, follow the Environmentally Regulated Disposal guidelines. Do not flush the medicine down a toilet or pour it into a drain (wastewater). The official guidance recommends disposing of the product through a designated medicine take-back program or following local pharmaceutical waste requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Primidona found in:

A-Z Index: